PET scan test for myelofibrosis using a special tracer
Part of Blood & lymphatic clinical trials.
This study uses a new type of PET/CT scan with a tracer called 68Ga-FAPI to help diagnose myelofibrosis, see how advanced it is, and check if treatment is working. It may help doctors better understand your condition and plan your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with or are suspected to have myelofibrosis, or you have myelofibrosis that hasn't been treated with ruxolitinib
- You are expected to live more than 3 months
- You agree to take part and can follow the study plan
- You can lie still on a scanning bed for about 20 minutes
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special type of PET scan (using a tracer called 18F-FAPI) can see myelofibrosis activity better than standard scans. It may help doctors track the disease more accurately without needing extra biopsies.
This trial uses a special PET scan tracer to see if it can help find and monitor diseases linked to a protein called FAP. It is for both cancer patients needing a biopsy and healthy volunteers.
This study tests how useful a special PET/CT scan (called 68Ga-FAPI) is for people who may have or have been diagnosed with cancer. The scan may help doctors see cancer activity more clearly.
This trial uses a special PET scan to look at diseases like cancer. It aims to see if this new imaging method can help doctors find or monitor disease better. This could be helpful for people with confirmed or suspected cancer or other conditions.
This study tests a new type of PET/CT scan (FAPI-74) to see if it can detect areas of scarring (fibrosis) in the body. It may help doctors better understand and monitor conditions like certain cancers, infections after transplants, and heart inflammation.
This study tests whether a special PET scan can better show how well chemotherapy given directly into the abdomen is working, compared to standard scans. This may help doctors see changes in tumors earlier and guide treatment.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.